





Sarcoidosis is a multi-system inflammatory disorder characterised by non-caseating 
granulomata (1-3). Clinical studies suggest that only 5% of patients with systemic 
sarcoidosis have overt cardiac involvement (4), yet autopsy series report cardiac 
involvement in up to 50% of cases with fatal sarcoidosis (2, 5), suggesting that 
cardiac sarcoidosis (CS) is frequently underdiagnosed with potentially life-
threatening consequences.   
 
An endomyocardial biopsy (EMB) showing non-caseating epithelioid granulomata is 
the diagnostic gold standard for CS, but it has a low diagnostic yield due to the 
patchy distribution of disease and the frequent location of granulomatous lesions in 
the basal, lateral and epicardial segments of the LV wall (6). EMB is also an invasive 
technique which is not universally available or performed without risk. Consequently, 
the diagnosis of CS is usually made on the basis of clinical and imaging features in 
conjunction with biopsy evidence from an extra-cardiac site as proposed by the 
Japanese Ministry of Health and Welfare (JMHW)(7).  
 
Late gadolinium enhancement (LGE) on cardiac magnetic resonance imaging (CMR) 
is a minor criterion in the JMHW guideline for the diagnosis of CS.  LGE in this 
context usually represents post-inflammatory myocardial scarring (8, 9) and is 
associated with adverse events including cardiac death (8, 10).  Myocardial 
inflammation can be visualised using 18F-fluorodeoxyglucose (FDG) positron 
emission tomography (PET), but the JMHW guideline includes only gallium 67 whole 
body planar imaging as a non-invasive marker of disease and there are scant data 






The development of hybrid positron emission tomography and magnetic resonance 
(PET/MR) imaging systems offers an efficient combined method for performing 
simultaneous structural, functional and tissue characterisation with CMR and 
metabolic imaging with PET. The aim of this study was to evaluate the performance 
of hybrid PET/MR in patients with suspected CS.  We postulated that hybrid PET/MR 
imaging is a more accurate technique than PET or CMR when performed alone for 
diagnosing active cardiac involvement in sarcoidosis and that multimodality imaging 






Subjects and study design 
The study cohort comprised consecutively evaluated patients with known or clinically 
suspected cardiac sarcoidosis seen in our centre between April 2012 and July 2013; 
7 (14%) had confirmed CS on endomyocardial biopsy; 44 (86%) patients with 
suspected CS had histologically proven extracardiac sarcoidosis. Patients were 
classified into those with and without evidence for CS using the 2006 revised 
Japanese Ministry of Health and Welfare (JMHW) guideline (Supplement Table 1) 
(7). The minor criterion, LGE, was excluded from this classification to enable its 
examination within this study.  
 
Study exclusion criteria were: inability to give informed consent; pregnant or breast-
feeding females; diabetes mellitus (due to the confounding influence of diabetes and 
insulin upon glucose metabolism); previous myocardial infarction or known coronary 
artery disease; allergy to gadolinium contrast agent; estimated glomerular filtration 
rate <30ml/min/1.73m2); claustrophobia and the presence of an implanted device 
incompatible with scanning at a 3 Tesla field strength.   
 
All subjects underwent clinical evaluation including history, physical examination, a 
12-lead electrocardiogram (ECG), 2-D and Doppler echocardiogram and baseline 
blood tests. Patients were reviewed every 6-12 months or earlier if clinically 
indicated. All eligible patients provided written informed consent and the study was 







All subjects underwent dietary preparation for 24 hours prior to PET/MR scanning 
using a high fat content diet and avoidance of carbohydrates, sugars, dairy or 
starchy foods followed by a prolonged fast for 12 hours to suppress physiological 
myocardial FDG uptake (13, 14). Adherence was confirmed through direct 
questioning. 
 
Hybrid PET/MR cardiac imaging protocol 
Following dietary preparation, all patients underwent a whole body hybrid PET/MR 
scan using an integrated whole-body PET/MR (3.0 Tesla) scanner (Biograph mMR; 
Siemens Healthcare, Erlangen, Germany). All subjects received an intravenous 
injection of 370 MBq of FDG at a mean of 64 minutes (± 13 minutes) (mean activity 
157 MBq ± 39MBq), prior to PET/MR image acquisition. PET myocardial perfusion 
imaging was not performed in this study to minimise radiation exposure as most 
subjects had already undergone coronary evaluation. A standard cardiac MR 
imaging protocol was performed to evaluate LGE simultaneously with FDG-PET 
acquisition following single breath-hold attenuation correction (AC) (Supplemental 
Figure 1)(15). T2-weighted imaging was not performed as this programme was 
unavailable on PET/MR at the time of this study.   
 
Cardiac MR imaging protocol 
Transverse half Fourier acquisition single-shot turbo spin-echo sequences were 
performed for 2-dimensional extracardiac anatomical imaging. Multiplanar balanced 
steady-state free precession cine sequences were acquired for wall motion 
abnormalities and volumetric analysis using the following acquisition parameters: 





256; echo time of 1.56 seconds; inversion time of 400-500ms; flip angle of 20 
degrees and slice thickness of 8mm with a 2mm gap. LGE imaging was performed 
using a standard segmented turbo fast low-angle shot two-dimensional inversion-
recovery gradient echo sequence 10 – 15 minutes after the bolus injection of the 
contrast agent injection Gadoterate meglumine, (gadolinium-DOTA, marketed as 
Dotarem, Guerbet S.A., Paris, France) at a dose of 0.1 mmol/kg. All images were 
acquired on breath hold and were ECG-triggered. The field of view was adjusted 
according to subject size (320-400mm). Matching contiguous short-axis views of the 
entire left ventricle were obtained for cine images and LGE.  
 
FDG PET/MR protocol 
FDG images were acquired using ECG-gating and three-dimensional image 
reconstruction (voxel size, 2 x 2 x 2 mm3) using ordinary Poisson ordered-subset 
expectation maximization with three iterations and 21 subsets, a Gaussian filter with 
5.0 mm full width at half maximum, and a 344 x 344 image matrix. For attenuation 
correction of the acquired PET data, a four-compartment model attenuation map (mu 
map) was calculated using the MR capabilities of the machine using fat-only and 
water-only Dixon-based sequences for automatic PET attenuation correction (16).  A 
full stack of short axis slices was acquired of the left ventricle (LV) from base to apex 
to exactly match the MR slice position for direct comparison.  
 
Image analysis 
The PET and LGE images were analysed qualitatively in consensus by two 
experienced readers blinded to the clinical characteristics of each subject.  The 





diffuse, focal or focal-on-diffuse (11, 14, 17, 25, 27).  None and diffuse uptake were 
categorized as a negative scan, and focal or focal-on-diffuse was categorized as a 
positive scan (11, 17). Regional analysis was performed by dividing 3 short axis 
slices (base, mid, apical) according to the conventional American Heart Association 
17 segment model; 16 segments, excluding the apex, were used for analysis.  Each 
of the 16 segments was visually assessed on a binary scale as positive for FDG 
tracer uptake (PET score: 1 abnormal increased uptake, 0 no increased uptake), and 
for the presence of LGE (LGE present 1, LGE absent 0).  Quantification analysis to 
assess heterogeneity was calculated for PET by dividing the maximal standardized 
uptake value (SUV) within the myocardium by the least avid segment (28).  Co-
localisation of LGE with FDG uptake was evaluated using co-registered LGE-FDG 
images generated by fusing individually matched LGE and PET short-axis slices 
through 3D-image reconstruction using OsiriX shareware (Version 5.8.5, Geneva, 
Switzerland (www.osirix-viewer.com). Finally, each PET/MR scan was assessed for 
the presence of extra-cardiac disease. 
 
Clinical outcomes 
Clinical information on adverse events was obtained via the electronic hospital 
records.  The pre-specified primary end point was a composite of all-cause mortality; 
aborted sudden cardiac death (either ventricular tachyarrhythmia leading to 
appropriate cardioverter-defibrillator discharge based on stored ECGs or 
successfully resuscitated cardiac arrest); symptomatic sustained ventricular 
arrhythmia; symptomatic bradyarrhythmia leading to pacemaker implantation or 





fall in LVEF >10%, non-sustained ventricular tachycardia (NSVT) or other cardiac-
related hospital admissions. 
 
Statistical analysis  
Statistical analysis was performed using SPSS (Version 23, IBM Corporation, Illinois, 
USA).  Kolmogorov-Smirnov analysis was performed to assess for normality. 
Continuous data were expressed as mean ± SD (for symmetrically distributed 
variables) and median ± interquartile range (for skewed variables).  Categorical data 
were reported as frequencies and percentages.  A Chi-squared test was used to test 
the association between categorical variables, and the independent Student’s t-test 
was performed to compare differences between continuous data in unrelated groups. 
The Bonferroni correction method was used to counteract for multiple comparisons. 
Segment wise (16 segments per scan) binary inter-method agreement between LGE 
and FDG was calculated using Cohen's kappa.  The follow-up period for each patient 
was calculated from the date of their first evaluation at our centre to the date of the 
study endpoint or primary adverse event. Event-free survival and cardiac survival 
(time to first event) were plotted as Kaplan–Meier curves.  The annual event rate 
according to the pattern of FDG uptake was calculated by dividing the number of 
patients reaching the composite endpoint by the total follow-up period for the 
endpoint.  
 
Univariate Cox regression analysis was performed to explore the association 
between individual variables and the time to event for the composite outcome.  
Multivariate Cox regression analysis was performed to delineate the influence of 





estimated using Chi square analysis. To ensure suitability, the proportional hazards 
assumption was investigated using Schoenfeld residuals (18). The multivariate 
analysis was limited as only 18 events were observed in this relatively small cohort 
and a minimum of 10 cardiac events were required per coefficient estimated by the 
model to ensure that the regression coefficients of the model were estimated with 
adequate precision. This allowed for just 2 regression coefficients to develop the risk 
model and thus the findings should be interpreted with caution. Each imaging 
component was investigated separately and adjusted for LVEF. Hybrid PET/MR was 
excluded from this model due to estimation problems and perfect prediction (19).  
 
All statistical tests were two-tailed, 95% confidence intervals were used to quantify 






A total of 51 patients (31 men and 20 women; mean age 50 ± 13 years (range 23-
80); 65% Caucasian; mean LV ejection fraction 53 ± 15%), with known or clinically 
suspected cardiac sarcoidosis were recruited. 44 patients (86%) had histologically 
proven extracardiac sarcoidosis and 7 (14%) had CS confirmed on EMB.  According 
to the JMHW guideline, the prevalence of CS was 65% (33/51).  The mean time 
interval between clinical suspicion of CS and PET/MR scan was 0.14 ± 0.28 years. 
The median follow-up time following scanning was 2.2 years (interquartile range 
(IQR) 1.7 – 3.5 years).  No patient was lost to follow-up. 
 
Clinical characteristics of the total cohort of 51 patients and JMHW+/- sub-groups 
are described in Table 1. There was no significant difference between groups in age, 
sex, self-reported ethnicity, incidence of coronary risk factors, immunosuppression 
use or NYHA functional class. However, LV ejection fraction was lower in the 




Twenty eight (55%) patients showed abnormal cardiac PET findings (17 focal and 11 
focal on diffuse uptake); twenty three (45%) patients had negative cardiac PET 
findings (19 no cardiac uptake (i.e. complete suppression of FDG uptake) and 4 with 
a diffuse pattern) (Table 2). 4 patients had abnormal PET findings in the right 
ventricle. One patient who had diffuse uptake had histological confirmation of active 
cardiac sarcoidosis on endomyocardial biopsy. Within the JMHW+ subgroup, PET 





although this did not reach statistical significance (61% vs 44%; p = 0.27). PET 
quantification analysis also confirmed that those fulfilling the JMHW criteria had 
greater SUV heterogeneity between different segments of the myocardium (when 
measured using the SUVmax to least avid segment ratio) than those JMHW- (mean 
1.94 ± 1.69 versus 1.29 ± 0.38; p = 0.04). Extracardiac abnormalities (in the form of 
lymphadenopathy or lymph node (LN) avidity, parenchymal disease or multi-system 
involvement with sarcoidosis) were seen in 29 (57%) of subjects.  
 
LGE was present in 32 (63%) patients and was more frequent in the JMHW+ 
subgroup (82% vs 22%; p <0.01). When PET and LGE abnormalities were 
considered together, 8 (16%) patients had no abnormalities, 11 (22%) subjects had 
PET abnormalities only, 15 (29%) subjects had LGE only and 17 (33%) had both 
PET and CMR abnormalities. PET/MR abnormalities were more frequently seen 
within the JMHW+ group compared with the JMHW- group (49% vs 6%; p = 0.005). 
  
The regional distribution of FDG-PET uptake and LGE in patients with CS according 
to JMHW guideline is presented in Figure 1.  There was a preponderance of FDG-
PET uptake and LGE in the basal to mid septum and inferolateral segments. FDG-
PET uptake was more extensive than LGE (277 (34%) versus 163 (20%) segments; 
kappa 0.14 [SE 0.02; 95% CI 0.10 – 0.18]). There was poor inter-method agreement 
for the regional distribution of FDG uptake and LGE (kappa 0.021 [SE 0.041; 95% CI 
-0.059 to 0.101]). Examples of patients with concordant and discordant FDG uptake 






The diagnostic performance of PET and LGE was also analysed (Table 3). Using the 
JMHW criteria as the gold standard, the sensitivity and specificity for diagnosing CS 
with myocardial FDG PET alone were 60% and 56% (PPV 71%, NPV 44%) (AUC 
0.58), respectively. When extracardiac abnormalities were considered together with 
abnormal myocardial uptake, the diagnostic sensitivity and specificity for PET rose to 
85% and 56%, respectively (PPV 78%, NPV 67%; AUC 0.7).  For LGE, the 
sensitivity and specificity for diagnosing CS were 82% and 78% (PPV 87%; NPV 
79%; AUC 0.8).  For hybrid PET/MR, the sensitivity was 94%; specificity 44%; PPV 
76%; NPV 80%; AUC 0.7. 
 
Patient outcomes 
Over a median follow-up duration of 2.2 years, 18 patients (35%) had adverse 
cardiac events, 16 of which were primary end-points and 2 secondary end-points. 
One (2%) patient died from acute AV block, 10 (20%) had symptomatic sustained 
ventricular tachyarrhythmia leading to appropriate defibrillator discharge, 5 (10%) 
were hospitalized for decompensated heart failure and 2 (4%) were admitted to 
hospital for other cardiac-related events (atrial arrhythmias necessitating ablation). 
No other patients developed atrioventricular block requiring pacemaker implantation 
during the course of the study.  
 
Those who suffered a cardiac event were more likely to have a lower LV ejection 
fraction (LVEF) and to meet the JMHW criteria than those without a cardiac event 






Clinical outcomes according to the PET/MR scan findings are illustrated using 
Kaplan–Meier survival curves (Figure 4). In the 8 patients with normal scan findings, 
there were no adverse events. In the 11 patients with abnormalities on PET imaging 
only (PET+LGE-), there was 1 event (9%).  In the 15 patients with LGE on PET/MR 
but no FDG uptake (LGE+PET-), there were 5 events (33%). In the 17 individuals 
with abnormal PET and LGE imaging (PET+LGE+), there were 12 events (71%) 
(Table 2, Figure 4A). Abnormalities detected on both PET and CMR was the 
strongest predictor of major adverse cardiac events when compared with the 
absence or singular abnormalities in either PET or LGE (p = 0.009) (Figure 4A) even 
after adjusting for age, sex and LVEF (Figure 4B).  
 
The annualised event rates for patients with ‘focal’, ‘focal on diffuse’, ‘complete 
suppression’ of cardiac uptake and ‘diffuse uptake’ were 28%, 13%, 8% and 24%, 
respectively (p=0.26). Patients with diffuse FDG uptake had a higher event rate than 
those with complete suppression of myocardial FDG uptake (24% versus 8%; p 
<0.05).  Patients with greater myocardial heterogeneity also had a higher event rate 
(SUVmax:least avid ratio 2.42 ± 2.2 versus 1.33 ± 0.4; p = 0.001). There was no 
association between the presence of extra-cardiac FDG uptake or number of 
affected systemic organs and adverse events. 
 
For LGE, the annualised event rate in the presence of LGE was 25% versus 3% 
when LGE was absent. One of the 19 subjects (5%) without LGE had a hospital 






Univariate predictors of adverse events are described in Table 4A. PET and LGE 
imaging components were considered separately within multivariate analyses. 
Hybrid PET/MR was excluded because of estimation problems due to absence of 
events in the PET/MR negative group (perfect prediction). Cardiac PET 
abnormalities when analysed independently were not predictive of primary adverse 
events (HR 2.29 [95% CI: 0.72-7.32; p = 0.16]) although RV avidity was predictive of 
adverse outcomes after adjusting for LVEF (HR 5.84 [95% CI: 1.12 – 30.4; p<0.04] 
(Table 4B). The presence of LGE was an independent predictor of major adverse 
cardiac events after adjusting for LVEF on multivariate analysis (HR 8.04 [95% CI: 
1.02 – 63.8; p =0.02]) (Table 4C, Figure 4B). This adverse effect persisted after 
adjusting for age, sex, LVEF and cardiac abnormalities found on PET (Table 4D, 
Figure 4B).  
 
In patients with CS according to the JMHW guidelines, the event rate and cardiac 
death rate was significantly higher than their JMHW-negative counterparts at 49% 
and 3% (versus 11% and 0%, respectively; p = 0.008). Fulfillment of the JMHW 
criteria was associated with an increased risk of an adverse event (HR 9.4; CI 1.24 – 
71.7, p < 0.05). Given the small study population and the small number of events, 






This study is the first to describe the use of simultaneous PET/MR imaging in the 
diagnosis of cardiac sarcoidosis. We have shown that this approach improves 
diagnostic sensitivity and the ability to risk-stratify patients according to the presence 
of scar and inflammation. The lower specificity of hybrid PET/MR compared to 
performing PET or LGE on CMR alone likely reflects the capability of the technique 
to detect pre-clinical stages of disease that are not included in the JMHW criteria 
which were used as the gold standard in this study. The relatively poor correlation 
between PET and LGE with respect to localisation of myocardial abnormalities 
reflects the different stages of disease at the time of imaging and suggests that the 
two modalities provide complementary information on disease pathophysiology. 
 
Cardiac sarcoidosis can precede, follow or be concurrent with involvement of other 
organs. The most common presentations of CS are atrioventricular nodal block, 
ventricular tachycardia and atrial arrhythmia, but extensive infiltration may also 
present with congestive cardiac failure and dilated cardiomyopathy. Because of its 
potential to cause life-threatening arrhythmias and heart failure, early diagnosis of 
cardiac sarcoidosis is essential. 
 
CMR provides a rapid, high-resolution, non-invasive method for diagnosing 
subclinical or clinically manifest CS. In the acute phase, CMR can show myocardial 
oedema and LV wall thickening, but CS is more frequently characterised by areas of 
left ventricular wall thinning and delayed gadolinium enhancement. The myocardial 
enhancement in both active inflammatory and advanced stages of CS shows various 





58 patients with biopsy-proven pulmonary sarcoidosis, CMR had a 100% sensitivity 
for CS when using the JMHW criteria as the gold standard (20). However, its 
specificity was only 78% and positive predictive value 55%, partly reflecting the non-
specific nature of some patterns of LGE. Two recent meta-analyses examining 694 
and 760 patients, respectively, have shown that LGE is associated with an adverse 
risk in patients with suspected or known CS.(21, 22) 
 
Several radionuclide techniques have been used to image systemic sarcoidosis but 
compared to FDG-PET, most have low sensitivity and limited spatial resolution for 
the detection of extra-pulmonary disease. Active inflammatory cells have high 
glycolytic activity and as a result have an 8-fold increase in ATP production than at 
baseline.(23) After crossing the cellular membrane via glucose transporters, FDG 
and glucose are phosphorylated by hexokinase, but FDG remains trapped within the 
cells and so can be imaged with PET. Unlike CMR, which detects areas of interstitial 
expansion caused by oedema or fibrosis, FDG PET detects active inflammatory 
cellular infiltrates. Several studies have suggested that FDG PET has a higher 
sensitivity and better spatial resolution for CS than single photon emitters such as 
technetium-99m, thallium-201 or gallium (17, 24-27) although the specificity often 
remains low. A meta-analysis of FDG PET (28), including 7 studies and 164 patients, 
calculated a pooled sensitivity of 89% and specificity of 78% for detecting CS. 
 
The interpretation of FDG PET for CS is complex but predominantly visual (13, 17, 
24, 26, 29). Semi-quantitative methods have shown that heterogeneity of PET 
uptake (measured by coefficient of variance or ratios of SUV uptake) may be more 





traditionally as a normal scan) have more events in this study, suggests that active 
disease may be missed on visual interpretation and that diffuse myocardial uptake 
may indeed be representative of myocardial disease in some patients. 
 
There are few data comparing FDG-PET and CMR in cardiovascular imaging (31-34) 
and even fewer in patients with suspected CS (30, 35). There is no series using 
contemporaneous scans, an important consideration as imaging findings can change 
with disease evolution and treatment. This study suggests that CMR and PET 
demonstrate different facets of the disease which together better describe the activity 
and extent of disease.  Gadolinium-enhanced CMR identifies expansion of the 
extracellular space, which is most prominent when fibrosis is present and thus may 
be better seen in later stages of disease.  In contrast, areas of active inflammatory 
cellular infiltration with little oedema may be better detected using FDG (31, 32, 36, 
37). A recent study of hybrid simultaneous PET/MR in myocarditis demonstrated 
good spatial agreement between LGE and FDG uptake and agreement between 
PET and oedema sensitive T2 weighted imaging (32, 34). PET/MR therefore offers 
enormous potential in the assessment of cardiac sarcoidosis. 
 
Study limitations 
Although several studies have attempted to determine the accuracy of cardiac PET 
for diagnosing CS, all (including the present study) have used the JMHW criteria as 
the reference standard. This may have an influence on the calculated sensitivity and 
specificity for CS in this study as the JMHW criteria have not been validated against 





Rhythm Society have recently proposed new guidelines for the diagnosis of CS 
which may improve diagnostic accuracy but require prospective evaluation (39).  
 
Image acquisition, interpretation and classification using PET is based upon 
internationally agreed methods. The European Association of Nuclear Medicine 
(EANM) Research Initiative (EARL) accreditation programme for standardisation of 
PET acquisition and reconstruction to enable independent quality control and 
assurance of PET, is only available for PETCT but not yet for PETMR and therefore 
was not used in this study (40). Whilst image interpretation is internationally defined, 
further understanding of normal fasting myocardial uptake patterns using FDG in 
controls is required. It is also possible that other novel tracers, such as the 
macrophage-directed somatostatin receptor ligands (68Galium DOTA-TOC or 
68Gallium DOTA-TATE), may provide some advantages over FDG (38, 41). CS is 
also associated with resting perfusion defects, however we did not perform PET 
perfusion evaluation as this would have incurred an additional radiation dose. 
Moreover, the local protocol for CMR did not include perfusion assessment as 
routine and as most patients had previously undergone coronary angiography this 
was excluded from the protocol. Similarly, the imaging protocol did not include T2-
weighted imaging as this technique was not available for PET/MR at the time of 
study. T2-weighted imaging techniques may offer improved sensitivity for identifying 
myocardial oedema in the acute phases of CS (42, 43). The use of 3D whole heart 
imaging datasets may also improve specificity and minimise image misregistration.  
Finally, among patients who are already on immunosuppressive medications, both 
CMR and PET may have reduced sensitivity to detect CS (30). In our study, 37% of 







The presence of LGE and FDG uptake on hybrid cardiac PET/MR identifies patients 
at higher risk of death, arrhythmia and decompensated heart failure and should be 
considered in the assessment of all patients presenting with suspected CS to 
determine disease activity and prognosis. Further studies are required to evaluate 
the potential of these imaging modalities for guiding and monitoring treatment. 
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